Investigation of solvent effect and NMR shielding tensors of p53 tumor-suppressor gene in drug design

被引:5
|
作者
Irani, S. [1 ]
Monajjemi, M. [2 ]
Honarparvar, B. [2 ]
Atyabi, S. M. [3 ]
Sadeghizadeh, M. [4 ]
机构
[1] Islamic Azad Univ, Dept Biol, Sci & Res Branch, Tehran, Iran
[2] Islamic Azad Univ, Dept Chem, Sci & Res Branch, Tehran, Iran
[3] Islamic Azad Univ, Dept Med Engn, Sci & Res Branch, Tehran, Iran
[4] Tarbiat Modares Univ, Dept Genet, Sch Biol Sci, Tehran, Iran
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2011年 / 6卷
关键词
p53; CUA; mutation; ab initio method; NMR shielding; GAS-PHASE; URACIL; BASES; PROTONATION; SPECTRUM; ACIDITY; THYMINE; RNA;
D O I
10.2147/IJN.S14632
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The p53 tumor-suppressor gene encodes a nuclear phosphoprotein with cancer-inhibiting properties. The most probable cancerous mutations occur as point mutations in exons 5 up to 8 of p53, as a base pair substitution that encompasses CUA and GAT sequences. As DNA drug design represents a direct genetic treatment of cancer, in the research reported computational drug design was carried out to explore, at the Hartree-Fock level, effects of solvents on the thermochemical properties and nuclear magnetic resonance (NMR) shielding tensors of some atoms of CUA involved in the hydrogen-bonding network. The observed NMR shielding variations of the solutes caused by solvent change seemed significant and were attributed to solvent polarity, and solute-solvent and solvent-solute hydrogen-bonding interactions. The results provide a reliable insight into the nature of mutation processes. However, to improve our knowledge of the hydration pattern more rigorous computations of the hydrated complexes are needed.
引用
收藏
页码:213 / 218
页数:6
相关论文
共 50 条
  • [31] THE P53 TUMOR-SUPPRESSOR GENE FREQUENTLY IS ALTERED IN GYNECOLOGIC CANCERS
    BERCHUCK, A
    KOHLER, MF
    MARKS, JR
    WISEMAN, R
    BOYD, J
    BAST, RC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (01) : 246 - 252
  • [32] PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53
    Yoon, Cheol-Hee
    Lee, Eun-Soo
    Lim, Dae-Seog
    Bae, Yong-Soo
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (19) : 7852 - 7857
  • [33] ABERRATIONS OF THE TUMOR-SUPPRESSOR P53 GENE AND P53 PROTEIN IN SOLAR KERATOSIS IN HUMAN SKIN
    TAGUCHI, M
    WATANABE, S
    YASHIMA, K
    MURAKAMI, Y
    SEKIYA, T
    IKEDA, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (04) : 500 - 503
  • [34] Tumor-suppressor p53: Implications for tumor development and prognosis
    Kirsch, DG
    Kastan, MB
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 3158 - 3168
  • [35] NEW TUMOR-SUPPRESSOR MAY RIVAL P53
    MARX, J
    SCIENCE, 1994, 264 (5157) : 344 - 345
  • [36] MUTATIONS OF THE P53 TUMOR-SUPPRESSOR GENE OCCUR INFREQUENTLY IN WILMS-TUMOR
    MALKIN, D
    SEXSMITH, E
    YEGER, H
    WILLIAMS, BRG
    COPPES, MJ
    CANCER RESEARCH, 1994, 54 (08) : 2077 - 2079
  • [37] Gene therapy for cancer - p53 tumor-suppressor gene key in ovarian cancer
    Brower, V
    GENETIC ENGINEERING NEWS, 2000, 20 (20): : 1 - +
  • [38] TUMOR-SUPPRESSOR P53 AND THE CELL-CYCLE
    PERRY, ME
    LEVINE, AJ
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1993, 3 (01) : 50 - 54
  • [39] OVEREXPRESSION OF P53 TUMOR-SUPPRESSOR PROTEIN IN POROKERATOSIS
    MAGEE, JW
    MCCALMONT, TH
    LEBOIT, PE
    ARCHIVES OF DERMATOLOGY, 1994, 130 (02) : 187 - 190
  • [40] TUMOR-SUPPRESSOR GENES - NO ROOM AT THE P53 INN
    PIETENPOL, JA
    NATURE, 1993, 365 (6441) : 17 - 18